Skip to main content
Venetoclax
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Tyrosine Kinase Inhibitor
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Read More
Supportive Care
Barriers to Initiating Oral Oncolytics by Specialty Pharmacy or Payers Can Affect Patient Outcomes
Leslie Wyatt
Read More
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Wayne Kuznar
Read More
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
Read More
FDA Updates
FDA News - January 2017
Read More
FDA Updates
FDA Approves Rucaparib and Companion Diagnostic for Patients with Advanced Ovarian Cancer
Read More
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Online First
FDA Updates, Venetoclax
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
New and Emerging Developments in the Management of Chronic Lymphocytic Leukemia: Role of the Pharmacist
Patrick J. Medina, PharmD, BCOP, FHOPA
Read More
Page 166 of 196
Results 1651 - 1660 of 1955